clinical trial · NCT07848295
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·phase1·not yet recruiting·n = 112
Clear Cell Renal Cell Carcinoma (ccRCC)BMS-986527NivolumabCabozantinib
brief summary
The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)
started
Dec 31, 2026
primary completion
Oct 18, 2030
completion
Apr 17, 2031
last updated
Sep 30, 2026
official title
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol